Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1972 1
1974 2
1975 1
1976 2
1977 3
1979 2
1980 1
1981 3
1982 7
1983 4
1984 10
1985 10
1986 6
1987 15
1988 13
1989 12
1990 7
1991 11
1992 16
1993 16
1994 27
1995 20
1996 21
1997 30
1998 24
1999 22
2000 26
2001 23
2002 23
2003 26
2004 37
2005 42
2006 45
2007 56
2008 45
2009 59
2010 48
2011 40
2012 38
2013 48
2014 36
2015 40
2016 39
2017 42
2018 30
2019 42
2020 28
2021 24
2022 21
2023 23
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

1,072 results

Results by year

Filters applied: . Clear all
Page 1
Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trial.
Dachs TM, Duca F, Rettl R, Binder-Rodriguez C, Dalos D, Ligios LC, Kammerlander A, Grünig E, Pretsch I, Steringer-Mascherbauer R, Ablasser K, Wargenau M, Mascherbauer J, Lang IM, Hengstenberg C, Badr-Eslam R, Kastner J, Bonderman D. Dachs TM, et al. Eur Heart J. 2022 Sep 21;43(36):3402-3413. doi: 10.1093/eurheartj/ehac389. Eur Heart J. 2022. PMID: 35909264 Free PMC article. Clinical Trial.
AIMS: The presence of pulmonary hypertension (PH) severely aggravates the clinical course of heart failure with preserved ejection fraction (HFpEF). ...Patients were recruited at five hospitals across Austria and Germany. Key eligibility criteria were mean pulmon …
AIMS: The presence of pulmonary hypertension (PH) severely aggravates the clinical course of heart failure with preserved ejec …
Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension.
Chin KM, Sitbon O, Doelberg M, Feldman J, Gibbs JSR, Grünig E, Hoeper MM, Martin N, Mathai SC, McLaughlin VV, Perchenet L, Poch D, Saggar R, Simonneau G, Galiè N. Chin KM, et al. J Am Coll Cardiol. 2021 Oct 5;78(14):1393-1403. doi: 10.1016/j.jacc.2021.07.057. J Am Coll Cardiol. 2021. PMID: 34593120 Free article. Clinical Trial.
BACKGROUND: In pulmonary arterial hypertension (PAH), there are no data comparing initial triple oral therapy with initial double oral therapy. OBJECTIVES: TRITON (The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patie …
BACKGROUND: In pulmonary arterial hypertension (PAH), there are no data comparing initial triple oral therapy with init …
Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension.
Grünig E, Jansa P, Fan F, Hauser JA, Pannaux M, Morganti A, Rofael H, Chin KM. Grünig E, et al. J Am Coll Cardiol. 2024 Jan 30;83(4):473-484. doi: 10.1016/j.jacc.2023.10.045. J Am Coll Cardiol. 2024. PMID: 38267108 Free article. Clinical Trial.
BACKGROUND: Endothelin receptor antagonist (ERA) and phosphodiesterase 5 inhibitor (PDE5i) combination therapy is recommended for low-/intermediate-risk pulmonary arterial hypertension (PAH) patients. A fixed-dose combination of the ERA macitentan and PDE5i t …
BACKGROUND: Endothelin receptor antagonist (ERA) and phosphodiesterase 5 inhibitor (PDE5i) combination therapy is recommended for low-/inter …
Dapagliflozin, sildenafil and their combination in monocrotaline-induced pulmonary arterial hypertension.
Tang Y, Tan S, Li M, Tang Y, Xu X, Zhang Q, Fu Q, Tang M, He J, Zhang Y, Zheng Z, Peng J, Zhu T, Xie W. Tang Y, et al. BMC Pulm Med. 2022 Apr 12;22(1):142. doi: 10.1186/s12890-022-01939-7. BMC Pulm Med. 2022. PMID: 35413880 Free PMC article.
The purpose of this study was to determine whether dapagliflozin can improve pulmonary vascular remodelling and the efficacy of dapagliflozin as an add-on therapy to sildenafil in rats with pulmonary arterial hypertension (PAH). ...RESULTS: Dapaglifloz …
The purpose of this study was to determine whether dapagliflozin can improve pulmonary vascular remodelling and the efficacy of dapag …
Pulmonary arterial hypertension and lung transplantation.
Lordan JL, Corris PA. Lordan JL, et al. Expert Rev Respir Med. 2011 Jun;5(3):441-54. doi: 10.1586/ers.11.21. Expert Rev Respir Med. 2011. PMID: 21702664 Review.
Transplantation remains the only therapeutic option for selected patients with advanced pulmonary arterial hypertension (PAH) who continue to deteriorate despite optimal pulmonary vasodilator therapy - including intravenous prostanoids and combi …
Transplantation remains the only therapeutic option for selected patients with advanced pulmonary arterial hypertension …
Combination Therapy in Pulmonary Arterial Hypertension-Targeting the Nitric Oxide and Prostacyclin Pathways.
Mandras S, Kovacs G, Olschewski H, Broderick M, Nelsen A, Shen E, Champion H. Mandras S, et al. J Cardiovasc Pharmacol Ther. 2021 Sep;26(5):453-462. doi: 10.1177/10742484211006531. Epub 2021 Apr 9. J Cardiovasc Pharmacol Ther. 2021. PMID: 33836637 Free PMC article. Review.
Pulmonary arterial hypertension (PAH) is a chronic and progressive disorder characterized by vascular remodeling of the small pulmonary arteries, resulting in elevated pulmonary vascular resistance and ultimately, right ventricular failure. ...T …
Pulmonary arterial hypertension (PAH) is a chronic and progressive disorder characterized by vascular remodeling of the …
Loss of lung microvascular endothelial Piezo2 expression impairs NO synthesis, induces EndMT, and is associated with pulmonary hypertension.
Tian S, Cai Z, Sen P, van Uden D, van de Kamp E, Thuillet R, Tu L, Guignabert C, Boomars K, Van der Heiden K, Brandt MM, Merkus D. Tian S, et al. Am J Physiol Heart Circ Physiol. 2022 Nov 1;323(5):H958-H974. doi: 10.1152/ajpheart.00220.2022. Epub 2022 Sep 23. Am J Physiol Heart Circ Physiol. 2022. PMID: 36149769 Free article.
Hence, we aimed to investigate the role of Piezo2 in regulation of pulmonary vascular function and structure, as well as its contribution to development of pulmonary arterial hypertension (PAH). ...Patient MVECs as well as animal models of pulmonary …
Hence, we aimed to investigate the role of Piezo2 in regulation of pulmonary vascular function and structure, as well as its contribu …
Pharmacotherapy of refractory pulmonary arterial hypertension.
Ahmed MS, Ghallab M, Ostrow T, Nashawi M, Alagha Z, Levine A, Aronow WS, Lanier GM. Ahmed MS, et al. Expert Opin Pharmacother. 2023 Sep-Dec;24(17):1861-1874. doi: 10.1080/14656566.2023.2257134. Epub 2023 Sep 12. Expert Opin Pharmacother. 2023. PMID: 37698041 Review.
INTRODUCTION: Treatment of refractory pulmonary arterial hypertension (PAH) is challenging and rarely the focus of reviews. ...AREAS COVERED: We conducted a comprehensive PubMed search on the relevant literature on treating PAH, with a focus on approved and i …
INTRODUCTION: Treatment of refractory pulmonary arterial hypertension (PAH) is challenging and rarely the focus of revi …
Integrative proteomics and phosphoproteomics in pulmonary arterial hypertension.
Xu W, Comhair SAA, Chen R, Hu B, Hou Y, Zhou Y, Mavrakis LA, Janocha AJ, Li L, Zhang D, Willard BB, Asosingh K, Cheng F, Erzurum SC. Xu W, et al. Sci Rep. 2019 Dec 9;9(1):18623. doi: 10.1038/s41598-019-55053-6. Sci Rep. 2019. PMID: 31819116 Free PMC article.
Pulmonary arterial endothelial cells (PAEC) are mechanistically linked to origins of pulmonary arterial hypertension (PAH). ...
Pulmonary arterial endothelial cells (PAEC) are mechanistically linked to origins of pulmonary arterial hyper …
Pulmonary arterial hypertension and women.
De Marco T. De Marco T. Cardiol Rev. 2006 Nov-Dec;14(6):312-8. doi: 10.1097/01.crd.0000240529.49704.2e. Cardiol Rev. 2006. PMID: 17053380 Review.
Pulmonary arterial hypertension (PAH) is a progressive disorder with a poor prognosis. ...Calcium channel blockers are beneficial in a small minority of patients. Prospective, controlled, randomized trials of approved vasodilator agents have enr …
Pulmonary arterial hypertension (PAH) is a progressive disorder with a poor prognosis. ...Calcium channel blockers are …
1,072 results